<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotective efficacy of YM872, a novel, highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-<z:chebi fb="0" ids="30768">propionic acid</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, was investigated in rats subjected to permanent occlusion of the left middle cerebral artery </plain></SENT>
<SENT sid="1" pm="."><plain>The rats were assessed either histologically or neurologically 24 hr or 1 wk after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>YM872 was intravenously infused for either 4 or 24 hr at dose rates of 0 to 20 mg/kg/hr starting 5 min after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> to examine the effect of prolonged treatment </plain></SENT>
<SENT sid="3" pm="."><plain>YM872 was then infused at 20 mg/kg/hr beginning 0 to 4 hr after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> to determine the efficacy time window </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, a 20 mg/kg/hr dose rate of YM872 was infused for 4 hr in single day- or 5-day repetitive-administrations to evaluate long-term benefits of the drug </plain></SENT>
<SENT sid="5" pm="."><plain>YM872 significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in both 4- and 24-hr treatment groups measured 24 hr after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>No difference was observed in the degree of protection between length of infusion </plain></SENT>
<SENT sid="7" pm="."><plain>Significant neuroprotection was maintained even when drug administration was delayed up to 2 hr after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A single YM872-administration significantly improved neurological deficit and reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (30%, P &lt;.01) measured 1 wk after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>YM872 treatment did not induce such adverse effects as physiological changes, serious behavioral abnormalities or nephrotoxicity </plain></SENT>
<SENT sid="10" pm="."><plain>These data suggest that the alpha-amino-3-hydroxy-5-methylisoxazole-4-<z:chebi fb="0" ids="30768">propionic acid</z:chebi> receptor plays a crucial role in the progression of neuronal damage in the early phase of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and that YM872 may be useful in treating <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>